{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T22:43:13Z","timestamp":1791844993743,"version":"4.3.4"},"reference-count":256,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T00:00:00Z","timestamp":1773532800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","award":["G0I2722N"],"award-info":[{"award-number":["G0I2722N"]}],"id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","award":["2133\/23"],"award-info":[{"award-number":["2133\/23"]}],"id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018693","name":"Horizon Europe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005026","name":"Stichting Tegen Kanker","doi-asserted-by":"publisher","award":["2022-178"],"award-info":[{"award-number":["2022-178"]}],"id":[{"id":"10.13039\/501100005026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005026","name":"Stichting Tegen Kanker","doi-asserted-by":"publisher","award":["2024-198"],"award-info":[{"award-number":["2024-198"]}],"id":[{"id":"10.13039\/501100005026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010663","name":"H2020 European Research Council","doi-asserted-by":"publisher","award":["101020342"],"award-info":[{"award-number":["101020342"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003975","name":"Israel Cancer Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003975","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005640","name":"Flight Attendant Medical Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005640","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001698","name":"Israel Cancer Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001698","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["31560"],"award-info":[{"award-number":["31560"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002803","name":"Fondazione Cariplo","doi-asserted-by":"publisher","award":["IG 2023"],"award-info":[{"award-number":["IG 2023"]}],"id":[{"id":"10.13039\/501100002803","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002803","name":"Fondazione Cariplo","doi-asserted-by":"publisher","award":["28922"],"award-info":[{"award-number":["28922"]}],"id":[{"id":"10.13039\/501100002803","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["S006825N"],"award-info":[{"award-number":["S006825N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["G045824N"],"award-info":[{"award-number":["G045824N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["G070622N"],"award-info":[{"award-number":["G070622N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.cell.2026.03.025","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T15:03:30Z","timestamp":1776351810000},"page":"2416-2440","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Mapping intratumor heterogeneity across layers for advancing immunotherapy"],"prefix":"10.1016","volume":"189","author":[{"given":"Jean-Christophe","family":"Marine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osnat","family":"Bartok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shira","family":"Sagie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro Paolo","family":"Vitiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Bardelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Weller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-Gen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Tonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefani","family":"Spranger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eytan","family":"Ruppin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yardena","family":"Samuels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cell.2026.03.025_bib1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1126\/science.959840","article-title":"The Clonal Evolution of Tumor Cell Populations","volume":"194","author":"Nowell","year":"1976","journal-title":"Science"},{"key":"10.1016\/j.cell.2026.03.025_bib2","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nature10762","article-title":"Clonal evolution in cancer","volume":"481","author":"Greaves","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.025_bib3","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","article-title":"Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future","volume":"168","author":"McGranahan","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.cell.2026.03.025_bib4","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cell.2026.03.025_bib5","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Dagogo-Jack","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.cell.2026.03.025_bib6","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41591-021-01233-9","article-title":"Intratumoral heterogeneity in cancer progression and response to immunotherapy","volume":"27","author":"Vitale","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2026.03.025_bib7","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41568-020-00302-4","article-title":"Non-genetic mechanisms of therapeutic resistance in cancer","volume":"20","author":"Marine","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cell.2026.03.025_bib8","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","article-title":"A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations","volume":"141","author":"Sharma","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.cell.2026.03.025_bib9","doi-asserted-by":"crossref","DOI":"10.1126\/science.aal2380","article-title":"Epigenetic plasticity and the hallmarks of cancer","volume":"357","author":"Flavahan","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.cell.2026.03.025_bib10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.molcel.2019.05.003","article-title":"Single-Cell RNA Sequencing in Cancer: Lessons Learned and Emerging Challenges","volume":"75","author":"Suv\u00e0","year":"2019","journal-title":"Mol. Cell"},{"key":"10.1016\/j.cell.2026.03.025_bib11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: New Dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cell.2026.03.025_bib12","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","article-title":"Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution","volume":"171","author":"McGranahan","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.cell.2026.03.025_bib13","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nrc3261","article-title":"Intra-tumour heterogeneity: a looking glass for cancer?","volume":"12","author":"Marusyk","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cell.2026.03.025_bib14","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.cell.2026.03.025_bib15","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.it.2016.04.008","article-title":"Tumor Heterogeneity and Tumor Immunity: A Chicken-and-Egg Problem","volume":"37","author":"Spranger","year":"2016","journal-title":"Trends Immunol."},{"key":"10.1016\/j.cell.2026.03.025_bib16","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1158\/2159-8290.CD-17-0256","article-title":"TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence","volume":"7","author":"Reuben","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cell.2026.03.025_bib17","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1245\/s10434-019-07338-3","article-title":"Tumor Heterogeneity Correlates with Less Immune Response and Worse Survival in Breast Cancer Patients","volume":"26","author":"McDonald","year":"2019","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.cell.2026.03.025_bib18","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41586-019-1032-7","article-title":"Neoantigen-directed immune escape in lung cancer evolution","volume":"567","author":"Rosenthal","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.025_bib19","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.41090","article-title":"Rejection of immunogenic tumor clones is limited by clonal fraction","volume":"7","author":"Gejman","year":"2018","journal-title":"eLife"},{"key":"10.1016\/j.cell.2026.03.025_bib20","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.cell.2019.08.032","article-title":"UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma","volume":"179","author":"Wolf","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.cell.2026.03.025_bib21","doi-asserted-by":"crossref","first-page":"805","DOI":"10.20892\/j.issn.2095-3941.2020.0177","article-title":"Evolving insights: how DNA repair pathways impact cancer evolution","volume":"17","author":"Zhou","year":"2020","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.cell.2026.03.025_bib22","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ado1641","article-title":"Heterogeneity and evolution of DNA mutation rates in microsatellite stable colorectal cancer","volume":"17","author":"Grassi","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cell.2026.03.025_bib23","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nrc3399","article-title":"DNA repair dysregulation from cancer driver to therapeutic target","volume":"12","author":"Curtin","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cell.2026.03.025_bib24","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","article-title":"The repertoire of mutational signatures in human cancer","volume":"578","author":"Alexandrov","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.025_bib25","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41568-021-00386-6","article-title":"Targeting the DNA damage response in immuno-oncology: developments and opportunities","volume":"21","author":"Chabanon","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cell.2026.03.025_bib26","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1038\/s41416-024-02848-8","article-title":"DNA repair-dependent immunogenic liabilities in colorectal cancer: opportunities from errors","volume":"131","author":"Amodio","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.cell.2026.03.025_bib27","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nature24673","article-title":"Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth","volume":"552","author":"Germano","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.025_bib28","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.cell.2026.03.025_bib29","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/2159-8290.CD-14-0863","article-title":"The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints","volume":"5","author":"Llosa","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cell.2026.03.025_bib30","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cell.2026.03.025_bib31","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41586-022-05593-1","article-title":"\u03b3\u03b4 T cells are effectors of immunotherapy in cancers with HLA class I defects","volume":"613","author":"de Vries","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.025_bib32","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1158\/2159-8290.CD-20-0987","article-title":"CD4 T Cell\u2013Dependent Rejection of Beta-2 Microglobulin Null Mismatch Repair\u2013Deficient Tumors","volume":"11","author":"Germano","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cell.2026.03.025_bib33","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/2159-8290.CD-19-0761","article-title":"The Cytosolic DNA-Sensing cGAS\u2013STING Pathway in Cancer","volume":"10","author":"Kwon","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cell.2026.03.025_bib34","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ccell.2020.11.006","article-title":"DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity","volume":"39","author":"Lu","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cell.2026.03.025_bib35","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ccell.2020.11.004","article-title":"MLH1 Deficiency-Triggered DNA Hyperexcision by Exonuclease 1 Activates the cGAS-STING Pathway","volume":"39","author":"Guan","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cell.2026.03.025_bib36","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1016\/j.celrep.2018.11.054","article-title":"PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer","volume":"25","author":"Ding","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.cell.2026.03.025_bib37","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-11048-5","article-title":"BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors","volume":"10","author":"Reisl\u00e4nder","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cell.2026.03.025_bib38","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1158\/2159-8290.CD-18-1218","article-title":"PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer","volume":"9","author":"Pantelidou","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cell.2026.03.025_bib39","article-title":"Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancer","volume":"11","author":"von Loga","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cell.2026.03.025_bib40","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/path.6228","article-title":"Genetic and immune landscape evolution in MMR-deficient colorectal cancer","volume":"262","author":"Challoner","year":"2024","journal-title":"J. Pathol."},{"key":"10.1016\/j.cell.2026.03.025_bib41","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1158\/0008-5472.CAN-25-2255","article-title":"Mismatch Repair as a Dynamic and Clinically Actionable Vulnerability in Cancer","volume":"85","author":"Piumatti","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.cell.2026.03.025_bib42","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1158\/2159-8290.CD-18-0150","article-title":"The Clinical Impact of the Genomic Landscape of Mismatch Repair\u2013Deficient Cancers","volume":"8","author":"Germano","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cell.2026.03.025_bib43","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1038\/s41591-024-02942-7","article-title":"Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses","volume":"30","author":"Friedman","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2026.03.025_bib44","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cell.2026.03.025_bib45","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.annonc.2024.11.012","article-title":"Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study","volume":"36","author":"Andr\u00e9","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.cell.2026.03.025_bib46","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(24)02848-4","article-title":"Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial","volume":"405","author":"Andr\u00e9","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.cell.2026.03.025_bib47","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/s41588-023-01499-4","article-title":"Mismatch repair deficiency is not sufficient to elicit tumor immunogenicity","volume":"55","author":"Westcott","year":"2023","journal-title":"Nat. Genet."},{"key":"10.1016\/j.cell.2026.03.025_bib48","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1053\/j.gastro.2021.06.064","article-title":"Immunogenomics of Colorectal Cancer Response to Checkpoint Blockade: Analysis of the KEYNOTE 177 Trial and Validation Cohorts","volume":"161","author":"Bortolomeazzi","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cell.2026.03.025_bib49","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-021-01166-3","article-title":"Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-\u03b3 signaling and tumor-infiltrating lymphocytes","volume":"14","author":"Wu","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.cell.2026.03.025_bib50","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nrc3298","article-title":"Evolutionary dynamics of carcinogenesis and why targeted therapy does not work","volume":"12","author":"Gillies","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cell.2026.03.025_bib51","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1158\/2159-8290.CD-15-1283","article-title":"Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer","volume":"6","author":"Russo","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cell.2026.03.025_bib52","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ccell.2018.06.004","article-title":"Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer","volume":"34","author":"Siravegna","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cell.2026.03.025_bib53","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13665","article-title":"Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer","volume":"7","author":"Van Emburgh","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cell.2026.03.025_bib54","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-16212-w","article-title":"Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures","volume":"11","author":"Vander Velde","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cell.2026.03.025_bib55","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41568-024-00737-z","article-title":"Cancer drug-tolerant persister cells: from biological questions to clinical opportunities","volume":"24","author":"Russo","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cell.2026.03.025_bib56","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1126\/science.aav4474","article-title":"Adaptive mutability of colorectal cancers in response to targeted therapies","volume":"366","author":"Russo","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.cell.2026.03.025_bib57","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/s41588-022-01105-z","article-title":"A modified fluctuation-test framework characterizes the population dynamics and mutation rate of colorectal cancer persister cells","volume":"54","author":"Russo","year":"2022","journal-title":"Nat. Genet."},{"key":"10.1016\/j.cell.2026.03.025_bib58","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1158\/2159-8290.CD-20-1588","article-title":"Adaptive Evolution: How Bacteria and Cancer Cells Survive Stressful Conditions and Drug Treatment","volume":"11","author":"Russo","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cell.2026.03.025_bib59","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature10738","article-title":"Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing","volume":"481","author":"Ding","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.025_bib60","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11060-020-03598-2","article-title":"Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor","volume":"151","author":"Hotchkiss","year":"2021","journal-title":"J. Neuro-oncol."},{"key":"10.1016\/j.cell.2026.03.025_bib61","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejca.2021.09.013","article-title":"Combining immune checkpoint inhibitors with chemotherapy in advanced solid tumours: A review","volume":"158","author":"Larroquette","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.cell.2026.03.025_bib62","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors","volume":"17","author":"Galluzzi","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.cell.2026.03.025_bib63","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.ccell.2025.05.010","article-title":"Induction of a mismatch repair deficient genotype by tailored chemical mutagenesis in experimental models of cancer","volume":"43","author":"Rousseau","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cell.2026.03.025_bib64","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.ccell.2025.05.014","article-title":"Cisplatin and temozolomide combinatorial treatment triggers hypermutability and immune surveillance in experimental cancer models","volume":"43","author":"Vitiello","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cell.2026.03.025_bib65","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1158\/2159-8290.CD-21-1434","article-title":"Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients","volume":"12","author":"Crisafulli","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cell.2026.03.025_bib66","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1200\/JCO.21.02583","article-title":"Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine\u2013DNA Methyltransferase\u2013Silenced Metastatic Colorectal Cancer: The MAYA Trial","volume":"40","author":"Morano","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cell.2026.03.025_bib67","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/j.cell.2021.03.009","article-title":"Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes","volume":"184","author":"Dentro","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.cell.2026.03.025_bib68","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.cell.2018.08.027","article-title":"The Multifaceted Role of Chromosomal Instability in Cancer and Its Microenvironment","volume":"174","author":"Bakhoum","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.cell.2026.03.025_bib69","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba0712","article-title":"Mechanisms generating cancer genome complexity from a single cell division error","volume":"368","author":"Umbreit","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.cell.2026.03.025_bib70","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/ng.3378","article-title":"An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers","volume":"47","author":"Chan","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.cell.2026.03.025_bib71","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1550341","article-title":"APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy","volume":"8","author":"Boichard","year":"2019","journal-title":"OncoImmunology"},{"key":"10.1016\/j.cell.2026.03.025_bib72","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","article-title":"Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity","volume":"160","author":"Rooney","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.cell.2026.03.025_bib73","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41568-019-0128-6","article-title":"Extrachromosomal oncogene amplification in tumour pathogenesis and evolution","volume":"19","author":"Verhaak","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cell.2026.03.025_bib74","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/nature21356","article-title":"Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity","volume":"543","author":"Turner","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.025_bib75","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41586-021-04116-8","article-title":"ecDNA hubs drive cooperative intermolecular oncogene expression","volume":"600","author":"Hung","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.025_bib76","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.88895","article-title":"Transcriptional immune suppression and up-regulation of double-stranded DNA damage and repair repertoires in ecDNA-containing tumors","volume":"12","author":"Lin","year":"2024","journal-title":"eLife"},{"key":"10.1016\/j.cell.2026.03.025_bib77","first-page":"OF1","article-title":"Cancer Evolution: A Multifaceted Affair","volume":"14","author":"Ciriello","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cell.2026.03.025_bib78","doi-asserted-by":"crossref","DOI":"10.1126\/science.adk9217","article-title":"Single-cell chromatin accessibility reveals malignant regulatory programs in primary human cancers","volume":"385","author":"Sundaram","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.cell.2026.03.025_bib79","doi-asserted-by":"crossref","DOI":"10.1126\/science.add5327","article-title":"Epigenetic plasticity cooperates with cell-cell interactions to direct pancreatic tumorigenesis","volume":"380","author":"Burdziak","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.cell.2026.03.025_bib80","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1038\/s43018-024-00838-6","article-title":"The neuroendocrine transition in prostate cancer is dynamic and dependent on ASCL1","volume":"5","author":"Romero","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.cell.2026.03.025_bib81","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41568-024-00757-9","article-title":"Epigenomic heterogeneity as a source of tumour evolution","volume":"25","author":"Laisn\u00e9","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cell.2026.03.025_bib82","article-title":"Combining spatial transcriptomics and ECM imaging in 3D for mapping cellular interactions in the tumor microenvironment","volume":"16","author":"Pentimalli","year":"2025","journal-title":"Cell Syst."},{"key":"10.1016\/j.cell.2026.03.025_bib83","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.cell.2023.11.037","article-title":"A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma","volume":"187","author":"Pozniak","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.cell.2026.03.025_bib84","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41586-021-04206-7","article-title":"Non-genetic determinants of malignant clonal fitness at single-cell resolution","volume":"601","author":"Fennell","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.025_bib85","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41587-020-0614-0","article-title":"Isolating live cell clones from barcoded populations using CRISPRa-inducible reporters","volume":"39","author":"Umkehrer","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.cell.2026.03.025_bib86","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/s41568-020-0275-9","article-title":"In vivo functional screening for systems-level integrative cancer genomics","volume":"20","author":"Weber","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cell.2026.03.025_bib87","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/s41586-022-05242-7","article-title":"A cellular hierarchy in melanoma uncouples growth and metastasis","volume":"610","author":"Karras","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.025_bib88","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.tcb.2025.01.009","article-title":"Decoding melanoma\u2019s cellular mosaic to unlock immunotherapy potential","volume":"35","author":"Pozniak","year":"2025","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.cell.2026.03.025_bib89","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/s41586-023-06130-4","article-title":"Hallmarks of transcriptional intratumour heterogeneity across a thousand tumours","volume":"618","author":"Gavish","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.025_bib90","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/s43018-025-00957-8","article-title":"The Curated Cancer Cell Atlas provides a comprehensive characterization of tumors at single-cell resolution","volume":"6","author":"Tyler","year":"2025","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.cell.2026.03.025_bib91","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.ccell.2024.08.005","article-title":"Cancer cell states: Lessons from ten years of single-cell RNA-sequencing of human tumors","volume":"42","author":"Tirosh","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cell.2026.03.025_bib92","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/pcmr.12873","article-title":"Cooperative behaviour and phenotype plasticity evolve during melanoma progression","volume":"33","author":"Rowling","year":"2020","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.cell.2026.03.025_bib93","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1158\/2159-8290.CD-23-1510","article-title":"Cell States in Cancer: Drivers, Passengers, and Trailers","volume":"14","author":"Gargiulo","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cell.2026.03.025_bib94","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41586-024-07302-6","article-title":"Decoding the interplay between genetic and non-genetic drivers of metastasis","volume":"629","author":"Karras","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.025_bib95","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.cell.2008.03.027","article-title":"The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells","volume":"133","author":"Mani","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.cell.2026.03.025_bib96","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ccr.2012.03.003","article-title":"Cancer Stem Cells: Impact, Heterogeneity, and Uncertainty","volume":"21","author":"Magee","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cell.2026.03.025_bib97","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.tcb.2018.12.001","article-title":"EMT Transition States during Tumor Progression and Metastasis","volume":"29","author":"Pastushenko","year":"2019","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.cell.2026.03.025_bib98","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41586-018-0040-3","article-title":"Identification of the tumour transition states occurring during EMT","volume":"556","author":"Pastushenko","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.025_bib99","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/s41586-020-03046-1","article-title":"Fat1 deletion promotes hybrid EMT state, tumour stemness and metastasis","volume":"589","author":"Pastushenko","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.025_bib100","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.cell.2011.07.026","article-title":"Stochastic State Transitions Give Rise to Phenotypic Equilibrium in Populations of Cancer Cells","volume":"146","author":"Gupta","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.cell.2026.03.025_bib101","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/sj.onc.1209814","article-title":"Neurotensin stimulates mitogenesis of prostate cancer cells through a novel c-Src\/Stat5b pathway","volume":"26","author":"Amorino","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.cell.2026.03.025_bib102","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrc3793","article-title":"Mechanisms of disseminated cancer cell dormancy: an awakening field","volume":"14","author":"Sosa","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cell.2026.03.025_bib103","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nature10137","article-title":"Role of YAP\/TAZ in mechanotransduction","volume":"474","author":"Dupont","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.025_bib104","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1158\/2159-8290.CD-24-0218","article-title":"A Molecular Voyage: Multiomics Insights into Circulating Tumor Cells","volume":"14","author":"Zhang","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cell.2026.03.025_bib105","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.cell.2018.06.025","article-title":"Toward Minimal Residual Disease-Directed Therapy in Melanoma","volume":"174","author":"Rambow","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.cell.2026.03.025_bib106","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/s43018-022-00402-0","article-title":"Mex3a marks drug-tolerant persister colorectal cancer cells that mediate relapse after chemotherapy","volume":"3","author":"\u00c1lvarez-Varela","year":"2022","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.cell.2026.03.025_bib107","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.ccell.2021.05.015","article-title":"Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma","volume":"39","author":"Marin-Bejar","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cell.2026.03.025_bib108","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.844866","article-title":"Mechanisms of MHC-I Downregulation and Role in Immunotherapy Response","volume":"13","author":"Taylor","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cell.2026.03.025_bib109","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/nature11538","article-title":"Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation","volume":"490","author":"Landsberg","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.025_bib110","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade","volume":"167","author":"Benci","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.cell.2026.03.025_bib111","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nature23669","article-title":"Identification of CMTM6 and CMTM4 as PD-L1 protein regulators","volume":"549","author":"Mezzadra","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.025_bib112","doi-asserted-by":"crossref","first-page":"6561","DOI":"10.1073\/pnas.1008942108","article-title":"Transmission of endoplasmic reticulum stress and pro-inflammation from tumor cells to myeloid cells","volume":"108","author":"Mahadevan","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cell.2026.03.025_bib113","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.ccell.2022.08.016","article-title":"Ablation of the endoplasmic reticulum stress kinase PERK induces paraptosis and type I interferon to promote anti-tumor T cell responses","volume":"40","author":"Mandula","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cell.2026.03.025_bib114","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/s41586-023-06464-z","article-title":"Non-cell-autonomous cancer progression from chromosomal instability","volume":"620","author":"Li","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.025_bib115","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41568-020-00312-2","article-title":"Endoplasmic reticulum stress signals in the tumour and its microenvironment","volume":"21","author":"Chen","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cell.2026.03.025_bib116","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.cell.2026.03.025_bib117","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer\u2013immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.025_bib118","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.trecan.2022.10.006","article-title":"Once upon a prime: DCs shape cancer immunity","volume":"9","author":"Zagorulya","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.cell.2026.03.025_bib119","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0092-8674(01)00455-X","article-title":"Regulation of T Cell Immunity by Dendritic Cells","volume":"106","author":"Lanzavecchia","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.cell.2026.03.025_bib120","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1146\/annurev-immunol-061020-053707","article-title":"Dendritic Cells Revisited","volume":"39","author":"Cabeza-Cabrerizo","year":"2021","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.cell.2026.03.025_bib121","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","article-title":"STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors","volume":"41","author":"Woo","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.cell.2026.03.025_bib122","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.immuni.2021.10.020","article-title":"Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ T cell immunity","volume":"55","author":"Duong","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.cell.2026.03.025_bib123","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nature23270","article-title":"In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target","volume":"547","author":"Manguso","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.025_bib124","doi-asserted-by":"crossref","first-page":"11942","DOI":"10.1073\/pnas.1003893107","article-title":"A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release","volume":"107","author":"Yang","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cell.2026.03.025_bib125","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ccell.2014.09.007","article-title":"Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity","volume":"26","author":"Broz","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cell.2026.03.025_bib126","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ccell.2016.06.003","article-title":"Critical Role for CD103(+)\/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma","volume":"30","author":"Roberts","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cell.2026.03.025_bib127","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1084\/jem.20020161","article-title":"The CD8+ Dendritic Cell Subset Selectively Endocytoses Dying Cells in Culture and In Vivo","volume":"195","author":"Iyoda","year":"2002","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cell.2026.03.025_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105514","article-title":"Intrinsic strategies for the evasion of cGAS-STING signaling-mediated immune surveillance in human cancer: How therapy can overcome them","volume":"166","author":"Zou","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.cell.2026.03.025_bib129","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nature06175","article-title":"Taking dendritic cells into medicine","volume":"449","author":"Steinman","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.025_bib130","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adf4726","article-title":"Architects of immunity: How dendritic cells shape CD8+ T cell fate in cancer","volume":"10","author":"Bhandarkar","year":"2025","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.cell.2026.03.025_bib131","doi-asserted-by":"crossref","first-page":"4512","DOI":"10.1016\/j.cell.2021.07.015","article-title":"CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment","volume":"184","author":"Di Pilato","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.cell.2026.03.025_bib132","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","article-title":"Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy","volume":"31","author":"Spranger","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cell.2026.03.025_bib133","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41577-024-01111-8","article-title":"Cancer immune evasion, immunoediting and intratumour heterogeneity","volume":"25","author":"Roerden","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cell.2026.03.025_bib134","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cell.2026.03.025_bib135","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1084\/jem.20101159","article-title":"Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells","volume":"208","author":"Fuertes","year":"2011","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cell.2026.03.025_bib136","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.025_bib137","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41590-020-00824-x","article-title":"The receptor DNGR-1 signals for phagosomal rupture to promote cross-presentation of dead-cell-associated antigens","volume":"22","author":"Canton","year":"2021","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cell.2026.03.025_bib138","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/nature07750","article-title":"Identification of a dendritic cell receptor that couples sensing of necrosis to immunity","volume":"458","author":"Sancho","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.025_bib139","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004159","article-title":"Dendritic cell-mediated cross presentation of tumor-derived peptides is biased against plasma membrane proteins","volume":"10","author":"Fessenden","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.cell.2026.03.025_bib140","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1182\/blood.V90.4.1594","article-title":"Presentation of exogenous protein antigens on major histocompatibility complex class I molecules by dendritic cells: pathway of presentation and regulation by cytokines","volume":"90","author":"Brossart","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.cell.2026.03.025_bib141","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1084\/jem.192.12.1685","article-title":"Cd8+ but Not Cd8- Dendritic Cells Cross-Prime Cytotoxic T Cells in Vivo","volume":"192","author":"den Haan","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cell.2026.03.025_bib142","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.ccell.2020.05.002","article-title":"Visualizing Synaptic Transfer of Tumor Antigens among Dendritic Cells","volume":"37","author":"Ruhland","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cell.2026.03.025_bib143","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.85263","article-title":"Decoupled neoantigen cross-presentation by dendritic cells limits anti-tumor immunity against tumors with heterogeneous neoantigen expression","volume":"12","author":"Nguyen","year":"2023","journal-title":"eLife"},{"key":"10.1016\/j.cell.2026.03.025_bib144","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010249","article-title":"Neoantigen architectures define immunogenicity and drive immune evasion of tumors with heterogenous neoantigen expression","volume":"12","author":"Roerden","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.cell.2026.03.025_bib145","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41586-020-2611-3","article-title":"cDC1 prime and are licensed by CD4+ T cells to induce anti-tumour immunity","volume":"584","author":"Ferris","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.025_bib146","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","article-title":"A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder","volume":"183","author":"Ott","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cell.2026.03.025_bib147","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.025_bib148","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","article-title":"Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial","volume":"565","author":"Keskin","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.025_bib149","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.cell.2018.09.018","article-title":"Evolution of Metastases in Space and Time under Immune Selection","volume":"175","author":"Angelova","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.cell.2026.03.025_bib150","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","article-title":"RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer","volume":"639","author":"Sethna","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.025_bib151","doi-asserted-by":"crossref","DOI":"10.1126\/science.adh8697","article-title":"Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity","volume":"384","author":"Houlahan","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.cell.2026.03.025_bib152","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1158\/1078-0432.CCR-18-1942","article-title":"WNT\/\u03b2-catenin pathway activation correlates with immune exclusion across human cancers","volume":"25","author":"Luke","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cell.2026.03.025_bib153","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0780-0","article-title":"Secondary resistance to immunotherapy associated with \u03b2-catenin pathway activation or PTEN loss in metastatic melanoma","volume":"7","author":"Trujillo","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.cell.2026.03.025_bib154","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41586-024-07254-x","article-title":"PGE2 limits effector expansion of tumour-infiltrating stem-like CD8+ T cells","volume":"629","author":"Lacher","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.025_bib155","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.cell.2015.08.015","article-title":"Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity","volume":"162","author":"Zelenay","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.cell.2026.03.025_bib156","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1126\/science.aac9935","article-title":"MYC regulates the antitumor immune response through CD47 and PD-L1","volume":"352","author":"Casey","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.cell.2026.03.025_bib157","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113295","article-title":"KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance","volume":"42","author":"Zavitsanou","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.cell.2026.03.025_bib158","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41586-024-07943-7","article-title":"CTLA4 blockade abrogates KEAP1\/STK11-related resistance to PD-(L)1 inhibitors","volume":"635","author":"Skoulidis","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.025_bib159","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2026.03.025_bib160","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/bs.ai.2015.12.003","article-title":"Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy","volume":"130","author":"Spranger","year":"2016","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.cell.2026.03.025_bib161","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/intimm\/dxw014","article-title":"Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment","volume":"28","author":"Spranger","year":"2016","journal-title":"Int. Immunol."},{"key":"10.1016\/j.cell.2026.03.025_bib162","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.jtho.2024.03.019","article-title":"EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47","volume":"19","author":"Hu","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.cell.2026.03.025_bib163","doi-asserted-by":"crossref","DOI":"10.1126\/science.adl6173","article-title":"Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity","volume":"385","author":"Wu","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.cell.2026.03.025_bib164","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.immuni.2025.06.005","article-title":"Mutant p53 exploits enhancers to elevate immunosuppressive chemokine expression and impair immune checkpoint inhibitors in pancreatic cancer","volume":"58","author":"Mahat","year":"2025","journal-title":"Immunity"},{"key":"10.1016\/j.cell.2026.03.025_bib165","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.immuni.2025.02.017","article-title":"Anti-vascular endothelial growth factor treatment potentiates immune checkpoint blockade through a BAFF- and IL-12-dependent reprogramming of the TME","volume":"58","author":"Benmebarek","year":"2025","journal-title":"Immunity"},{"key":"10.1016\/j.cell.2026.03.025_bib166","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.1096","article-title":"Interaction between VEGF-A and immune checkpoint targets in triple-negative breast cancer and mechanisms of immune evasion and tumor progression","volume":"42","author":"Seager","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cell.2026.03.025_bib167","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1084\/jem.20130783","article-title":"p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells","volume":"210","author":"Iannello","year":"2013","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cell.2026.03.025_bib168","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nature05529","article-title":"Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas","volume":"445","author":"Xue","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.025_bib169","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","article-title":"Loss of PTEN Promotes Resistance to T Cell\u2013Mediated Immunotherapy","volume":"6","author":"Peng","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cell.2026.03.025_bib170","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1366260","article-title":"Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges","volume":"15","author":"Xiang","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cell.2026.03.025_bib171","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41568-021-00413-6","article-title":"Overcoming TGF\u03b2-mediated immune evasion in cancer","volume":"22","author":"Tauriello","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cell.2026.03.025_bib172","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41577-024-01026-4","article-title":"Cancer cell metabolism and antitumour immunity","volume":"24","author":"De Martino","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cell.2026.03.025_bib173","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s12276-023-01028-7","article-title":"Immune regulation through tryptophan metabolism","volume":"55","author":"Seo","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.cell.2026.03.025_bib174","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1161\/ATVBAHA.111.226837","article-title":"Regulation of Lymphocyte Function by Adenosine","volume":"32","author":"Linden","year":"2012","journal-title":"Vasc. Biol."},{"key":"10.1016\/j.cell.2026.03.025_bib175","doi-asserted-by":"crossref","DOI":"10.3390\/cells9040992","article-title":"Hypoxia-Driven Immune Escape in the Tumor Microenvironment","volume":"9","author":"Vito","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.cell.2026.03.025_bib176","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1158\/0008-5472.CAN-15-1439","article-title":"STK11\/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment","volume":"76","author":"Koyama","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.cell.2026.03.025_bib177","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccr.2004.06.007","article-title":"The LKB1 tumor suppressor negatively regulates mTOR signaling","volume":"6","author":"Shaw","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cell.2026.03.025_bib178","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.tips.2025.06.008","article-title":"Targeting LKB1\/STK11-mutant cancer: distinct metabolism, microenvironment, and therapeutic resistance","volume":"46","author":"Minor","year":"2025","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.cell.2026.03.025_bib179","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrc2676","article-title":"The LKB1\u2013AMPK pathway: metabolism and growth control in tumour suppression","volume":"9","author":"Shackelford","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cell.2026.03.025_bib180","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cell.2026.03.025_bib181","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1038\/s42255-024-01105-9","article-title":"Cancer tissue of origin constrains the growth and metabolism of metastases","volume":"6","author":"Sivanand","year":"2024","journal-title":"Nat. Metab."},{"key":"10.1016\/j.cell.2026.03.025_bib182","doi-asserted-by":"crossref","first-page":"4734","DOI":"10.1016\/j.cell.2021.08.003","article-title":"Spatially organized multicellular immune hubs in human colorectal cancer","volume":"184","author":"Pelka","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.cell.2026.03.025_bib183","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.cell.2020.07.005","article-title":"Coordinated Cellular Neighborhoods Orchestrate Antitumoral Immunity at the Colorectal Cancer Invasive Front","volume":"182","author":"Sch\u00fcrch","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.cell.2026.03.025_bib184","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2023.102342","article-title":"Game of Omes: ribosome profiling expands the MHC-I immunopeptidome","volume":"83","author":"Holly","year":"2023","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.cell.2026.03.025_bib185","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2022.100230","article-title":"MHC Class I Immunopeptidome: Past, Present, and Future","volume":"21","author":"Yewdell","year":"2022","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.cell.2026.03.025_bib186","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.tcb.2019.09.004","article-title":"Peptide Channeling: The Key to MHC Class I Immunosurveillance?","volume":"29","author":"Yewdell","year":"2019","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.cell.2026.03.025_bib187","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41586-022-04682-5","article-title":"Landscape of helper and regulatory antitumour CD4+ T cells in melanoma","volume":"605","author":"Oliveira","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.025_bib188","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1158\/2159-8290.CD-20-0377","article-title":"An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor GrowthATLAS-Identified","volume":"11","author":"Lam","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cell.2026.03.025_bib189","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/s41587-024-02420-y","article-title":"A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy","volume":"43","author":"Huber","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.cell.2026.03.025_bib190","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-62647-4","article-title":"Sensitive neoantigen discovery by real-time mutanome-guided immunopeptidomics","volume":"16","author":"Shapiro","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cell.2026.03.025_bib191","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/s43018-023-00548-5","article-title":"The immunopeptidome landscape associated with T cell infiltration, inflammation and immune editing in lung cancer","volume":"4","author":"Kraemer","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.cell.2026.03.025_bib192","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41586-020-03054-1","article-title":"Anti-tumour immunity induces aberrant peptide presentation in melanoma","volume":"590","author":"Bartok","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.025_bib193","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1016\/j.cell.2021.05.038","article-title":"Pharmacologic modulation of RNA splicing enhances anti-tumor immunity","volume":"184","author":"Lu","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.cell.2026.03.025_bib194","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau5516","article-title":"Noncoding regions are the main source of targetable tumor-specific antigens","volume":"10","author":"Laumont","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cell.2026.03.025_bib195","article-title":"RNA editing derived epitopes function as cancer antigens to elicit immune responses","volume":"9","author":"Zhang","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cell.2026.03.025_bib196","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1016\/j.molcel.2021.09.002","article-title":"Oncogene-dependent sloppiness in mRNA translation","volume":"81","author":"Champagne","year":"2021","journal-title":"Mol. Cell"},{"key":"10.1016\/j.cell.2026.03.025_bib197","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/s41586-022-04499-2","article-title":"Tryptophan depletion results in tryptophan-to-phenylalanine substitutants","volume":"603","author":"Pataskar","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.025_bib198","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.ccell.2025.03.003","article-title":"Translation dysregulation in cancer as a source for targetable antigens","volume":"43","author":"Weller","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cell.2026.03.025_bib199","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2025.100951","article-title":"Deleterious KOs in the HLA Class I Antigen Processing and Presentation Machinery Induce Distinct Changes in the Immunopeptidome","volume":"24","author":"Shapiro","year":"2025","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.cell.2026.03.025_bib200","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.ccell.2020.03.016","article-title":"Cathepsin S Regulates Antigen Processing and T Cell Activity in Non-Hodgkin Lymphoma","volume":"37","author":"Dheilly","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cell.2026.03.025_bib201","doi-asserted-by":"crossref","first-page":"20785","DOI":"10.1073\/pnas.2003358117","article-title":"Epigenetic loss of the transfer RNA-modifying enzyme TYW2 induces ribosome frameshifts in colon cancer","volume":"117","author":"Rossell\u00f3-Tortella","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cell.2026.03.025_bib202","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax7918","article-title":"Neoantigen quality, not quantity","volume":"11","author":"McGranahan","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cell.2026.03.025_bib203","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1158\/2159-8290.CD-18-1494","article-title":"Unique Neoantigens Arise from Somatic Mutations in Patients with Gastrointestinal Cancers","volume":"9","author":"Parkhurst","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cell.2026.03.025_bib204","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nature24473","article-title":"A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy","volume":"551","author":"\u0141uksza","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.025_bib205","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41586-022-04735-9","article-title":"Neoantigen quality predicts immunoediting in survivors of pancreatic cancer","volume":"606","author":"\u0141uksza","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.025_bib206","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012405","article-title":"PROTAC-based nanoantigens promote cross-presentation and trafficking of dendritic cell vaccine for enhanced antitumor efficacy","volume":"13","author":"Liu","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.cell.2026.03.025_bib207","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.semcancer.2020.02.006","article-title":"PROTACs: A novel strategy for cancer therapy","volume":"67","author":"Liu","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.cell.2026.03.025_bib208","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13045-025-01765-4","article-title":"Recent advances in targeting protein degradation for tumor immunotherapy","volume":"19","author":"Li","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.cell.2026.03.025_bib209","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41591-022-02163-w","article-title":"Persistent mutation burden drives sustained anti-tumor immune responses","volume":"29","author":"Niknafs","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2026.03.025_bib210","first-page":"1","article-title":"Five dominant amino acid substitution signatures shape tumour immunity","author":"Juh\u00e1sz","year":"2026","journal-title":"Mol. Syst. Biol."},{"key":"10.1016\/j.cell.2026.03.025_bib211","doi-asserted-by":"crossref","DOI":"10.1172\/JCI129466","article-title":"Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma","volume":"131","author":"Peri","year":"2021","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.cell.2026.03.025_bib212","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s43018-021-00197-6","article-title":"A machine learning model for ranking candidate HLA class I neoantigens based on known neoepitopes from multiple human tumor types","volume":"2","author":"Gartner","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.cell.2026.03.025_bib213","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1016\/j.cell.2022.06.035","article-title":"Cancer vaccines: Building a bridge over troubled waters","volume":"185","author":"Sellars","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.cell.2026.03.025_bib214","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/s43018-021-00247-z","article-title":"Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer","volume":"2","author":"Westcott","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.cell.2026.03.025_bib215","first-page":"OF1","article-title":"Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer","volume":"16","author":"Gumpert","year":"2025","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cell.2026.03.025_bib216","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/2159-8290.CD-16-0828","article-title":"Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non\u2013Small Cell Lung Cancer","volume":"7","author":"Anagnostou","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cell.2026.03.025_bib217","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","article-title":"Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab","volume":"171","author":"Riaz","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.cell.2026.03.025_bib218","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112638","article-title":"Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers","volume":"13","author":"Amodio","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.cell.2026.03.025_bib219","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.cell.2021.01.002","article-title":"Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition","volume":"184","author":"Litchfield","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.cell.2026.03.025_bib220","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1126\/science.aao4572","article-title":"Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy","volume":"359","author":"Chowell","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.cell.2026.03.025_bib221","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.645770","article-title":"IFN\u03b3 Modulates the Immunopeptidome of Triple Negative Breast Cancer Cells by Enhancing and Diversifying Antigen Processing and Presentation","volume":"12","author":"Goncalves","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cell.2026.03.025_bib222","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1074\/mcp.M116.060350","article-title":"Human Leukocyte Antigen (HLA) Peptides Derived from Tumor Antigens Induced by Inhibition of DNA Methylation for Development of Drug-facilitated Immunotherapy","volume":"15","author":"Shraibman","year":"2016","journal-title":"Mol. Cell. Proteom."},{"key":"10.1016\/j.cell.2026.03.025_bib223","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2021.100105","article-title":"The Effect of Interferons on Presentation of Defective Ribosomal Products as HLA Peptides","volume":"20","author":"Komov","year":"2021","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.cell.2026.03.025_bib224","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.it.2011.08.001","article-title":"DRiPs solidify: progress in understanding endogenous MHC class I antigen processing","volume":"32","author":"Yewdell","year":"2011","journal-title":"Trends Immunol."},{"key":"10.1016\/j.cell.2026.03.025_bib225","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.108815","article-title":"Most non-canonical proteins uniquely populate the proteome or immunopeptidome","volume":"34","author":"Ruiz Cuevas","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.cell.2026.03.025_bib226","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1158\/2326-6066.CIR-19-0886","article-title":"Identification of the Cryptic HLA-I Immunopeptidome","volume":"8","author":"Erhard","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.cell.2026.03.025_bib227","article-title":"Pharmacologic RNA splicing modulation: a novel mechanism to enhance neoantigen-directed anti-tumor immunity and immunotherapy response","volume":"6","author":"Elliott","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.cell.2026.03.025_bib228","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102389","article-title":"NMD inhibition by 5-azacytidine augments presentation of immunogenic frameshift-derived neoepitopes","volume":"24","author":"Becker","year":"2021","journal-title":"Iscience"},{"key":"10.1016\/j.cell.2026.03.025_bib229","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1158\/1078-0432.CCR-19-0596","article-title":"Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation","volume":"25","author":"Jaeger","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cell.2026.03.025_bib230","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1800957","article-title":"Characterization of the human tumor microbiome reveals tumor-type specific intra-cellular bacteria","volume":"9","author":"Livyatan","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.cell.2026.03.025_bib231","article-title":"Intratumoral bacteria may elicit chemoresistance by metabolizing anticancer agents","volume":"5","author":"Geller","year":"2017","journal-title":"Mol. Cell. Oncol."},{"key":"10.1016\/j.cell.2026.03.025_bib232","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1126\/science.aay9189","article-title":"The human tumor microbiome is composed of tumor type\u2013specific intracellular bacteria","volume":"368","author":"Nejman","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.cell.2026.03.025_bib233","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.cell.2019.07.008","article-title":"Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes","volume":"178","author":"Riquelme","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.cell.2026.03.025_bib234","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/s41586-021-03368-8","article-title":"Identification of bacteria-derived HLA-bound peptides in melanoma","volume":"592","author":"Kalaora","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.025_bib235","article-title":"Lymphodepleting chemotherapy potentiates neoantigen-directed T cell therapy by enhancing antigen presentation","volume":"6","author":"Sagie","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.cell.2026.03.025_bib236","doi-asserted-by":"crossref","first-page":"13964","DOI":"10.1093\/nar\/gkae1110","article-title":"Chemotherapeutic agents and leucine deprivation induce codon-biased aberrant protein production in cancer","volume":"52","author":"Kochavi","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.cell.2026.03.025_bib237","doi-asserted-by":"crossref","DOI":"10.1172\/JCI138740","article-title":"Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control","volume":"131","author":"Lhuillier","year":"2021","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.cell.2026.03.025_bib238","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s43018-025-00917-2","article-title":"Hallmarks of artificial intelligence contributions to precision oncology","volume":"6","author":"Chang","year":"2025","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.cell.2026.03.025_bib239","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/s41592-018-0229-2","article-title":"Deep generative modeling for single-cell transcriptomics","volume":"15","author":"Lopez","year":"2018","journal-title":"Nat. Methods"},{"key":"10.1016\/j.cell.2026.03.025_bib240","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-019-1663-x","article-title":"PAGA: graph abstraction reconciles clustering with trajectory inference through a topology preserving map of single cells","volume":"20","author":"Wolf","year":"2019","journal-title":"Genome Biol."},{"key":"10.1016\/j.cell.2026.03.025_bib241","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.cell.2018.09.006","article-title":"A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade","volume":"175","author":"Jerby-Arnon","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.cell.2026.03.025_bib242","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.cell.2018.08.039","article-title":"A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging","volume":"174","author":"Keren","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.cell.2026.03.025_bib243","article-title":"NeoPrecis: Enhancing Immunotherapy Response Prediction through Integration of Qualified Immunogenicity and Clonality-Aware Neoantigen Landscapes","author":"Lee","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.cell.2026.03.025_bib244","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adp4670","article-title":"Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanoma","volume":"10","author":"Tarantino","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.cell.2026.03.025_bib245","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-43172-8","article-title":"Deep learning of cell spatial organizations identifies clinically relevant insights in tissue images","volume":"14","author":"Wang","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cell.2026.03.025_bib246","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1038\/s41588-025-02351-7","article-title":"Spatial signatures for predicting immunotherapy outcomes using multi-omics in non-small cell lung cancer","volume":"57","author":"Aung","year":"2025","journal-title":"Nat. Genet."},{"key":"10.1016\/j.cell.2026.03.025_bib247","article-title":"Spatial Multi-omics and Deep Learning Reveal Fingerprints of Immunotherapy Response and Resistance in Hepatocellular Carcinoma","author":"Wu","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.cell.2026.03.025_bib248","article-title":"Predicting the tumor microenvironment composition and immunotherapy response in non-small cell lung cancer from digital histopathology images","volume":"8","author":"Patkar","year":"2024","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.cell.2026.03.025_bib249","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/s43018-024-00793-2","article-title":"A deep-learning framework to predict cancer treatment response from histopathology images through imputed transcriptomics","volume":"5","author":"Hoang","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.cell.2026.03.025_bib250","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.ccell.2022.07.004","article-title":"Pan-cancer integrative histology-genomic analysis via multimodal deep learning","volume":"40","author":"Chen","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cell.2026.03.025_bib251","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1001\/jamaoncol.2024.5356","article-title":"Deep Learning Model for Predicting Immunotherapy Response in Advanced Non\u2212Small Cell Lung Cancer","volume":"11","author":"Rakaee","year":"2025","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.cell.2026.03.025_bib252","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/s41586-021-04278-5","article-title":"Multi-omic machine learning predictor of breast cancer therapy response","volume":"601","author":"Sammut","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.025_bib253","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1080\/14737159.2025.2581687","article-title":"Digital pathology and AI: enhancing molecular diagnostics in low- and middle-income countries","volume":"25","author":"Rahman","year":"2025","journal-title":"Expert Rev. Mol. Diagn."},{"key":"10.1016\/j.cell.2026.03.025_bib254","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1078822","article-title":"Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patients","volume":"12","author":"Prelaj","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cell.2026.03.025_bib255","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/s41591-024-03398-5","article-title":"Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data","volume":"31","author":"Yoo","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2026.03.025_bib256","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1158\/2326-6066.CIR-24-0164","article-title":"Integrated germline and somatic features reveal divergent immune pathways driving response to immune checkpoint blockade","volume":"12","author":"Sears","year":"2024","journal-title":"Cancer Immunol. Res."}],"container-title":["Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0092867426003260?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0092867426003260?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T12:32:55Z","timestamp":1779539575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0092867426003260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":256,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0092867426003260"],"URL":"https:\/\/doi.org\/10.1016\/j.cell.2026.03.025","relation":{},"ISSN":["0092-8674"],"issn-type":[{"value":"0092-8674","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mapping intratumor heterogeneity across layers for advancing immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cell.2026.03.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}